GTC/Ovation's recombinant antithrombin under US review
This article was originally published in Scrip
Executive Summary
Having acquired the US rights forGTC Biotherapeutics' ATryn (recombinant antithrombin alfa) in August, Ovation Pharmaceuticalssays that the US FDAhas now accepted the BLA for the product, which is produced in the milk of transgenic goats. GTC has received $2 million in milestone payments from Ovation following the submission.